ORIGINAL ARTICLE

Midlife blood pressure predicts future diastolic dysfunction independently of blood pressure

Arjun Kumar Ghosh,1,2 Alun David Hughes,3 Darrel Francis,1 Nishi Chaturvedi,3 Denis Pellerin,2 John Deanfield,3 Diana Kuh,4 Jamil Mayet,1 Rebecca Hardy,4 on behalf of the MRC NSHD Scientific and Data Collection Team

ABSTRACT

Objectives High blood pressure (BP) is associated with diastolic dysfunction, but the consequence of elevated BP over the adult life course on diastolic function is unknown. We hypothesised that high BP in earlier adulthood would be associated with impaired diastolic function independent of current BP.

Methods Participants in the Medical Research Council National Survey of Health and Development birth cohort (n=1653) underwent investigations including echocardiography at age 60–64 years. The relationships between adult BP, antihypertensive treatment (HTT) and echocardiographic measures of diastolic function were assessed using adjusted regression models.

Results Increased systolic BP (SBP) at ages 36, 43 and 53 years was predictive of increased E/e′ and increased left atrial volume. These effects were only partially explained by SBP at 60–64 years and increased left ventricular mass. HTT was also associated with poorer diastolic function after adjustment for SBP at 60–64 years. Faster rates of increase in SBP in midlife were also associated with increased poorer diastolic function.

Conclusions High SBP in midlife is associated with poorer diastolic function at age 60–64 years. Early identification of individuals with high BP or rapid rises in BP may be important for prevention of impaired cardiac function in later life.

INTRODUCTION

With an ageing population, and better postmyocardial infarction survival, the burden of congestive heart failure is increasing and represents a major public health challenge.1 Diastolic dysfunction is common in people over 45 years with a prevalence of 28% in a large community study,1 and is a precursor of heart failure with preserved ejection fraction (HFPEF).2 Echocardiographic measures of diastolic dysfunction and elevated left ventricular (LV) filling pressure also predict a threefold increased cardiac mortality and a twofold increased all-cause mortality in those with normal ejection fractions.2 3 High systolic blood pressure (SBP) is an important cause of diastolic dysfunction, and there is evidence that raised antecedent SBP in early and midadulthood is associated with increased risk of heart failure,4 and elevated risk of cardiovascular mortality independent of current blood pressure (BP).5 However, there has been limited work investigating the effects of longitudinal changes in BP over adulthood on diastolic function.6 We have previously shown that increased SBP in adult midlife is associated with increased LV mass in later life independent of later SBP and that rapid rises in midlife SBP might play a key role.7 We hypothesised that a similar relationships may exist between SBP and diastolic function and also aimed to determine the extent to which this might be due to increased LV mass. In addition, we examined the association between antihypertensive treatment (HTT) and subsequent diastolic function.

METHODS

Study patients

The UK Medical Research Council National Survey of Health and Development (MRC NSHD) is a prospective birth cohort study of singleton births that occurred in 1 week of March 1946 in England, Scotland and Wales (5362 births; 2547 women, 2815 men). Follow-up has included over 20 contacts with the whole cohort between birth and the most recent data collection when the participants were between 60 and 64 years of age.7 Study members still alive and with a known current address in England, Scotland or Wales were invited for an assessment at one of six clinical research facilities (CRFs) or to be visited by a research nurse at home. Invitations were not sent to those who had died (N=778), who were living abroad (N=570), had previously withdrawn from the study (N=594) or had been lost to follow-up (N=564). Of the 2856 invited participants, 2229 (78%) were assessed: 1690 (59%) attended a CRF and the remaining 539 were visited at home. Echocardiography was only carried out at the CRF (N=1653). The participating sample remains broadly representative of native born British men and women of the same age.8

Ethical approval was obtained from the Central Manchester Research Ethics Committee (07/H1008/168) and the Scotland A Research Ethics Committee. Written informed consent was obtained from each study member at each stage of data collection.

Anthropometry and BP measurement

Height and weight were measured at the clinic visit and body mass index (BMI) calculated. Sitting brachial BP was measured in the upper right arm with an appropriately sized cuff after 5 min of rest at 53 years and 60–64 years with the second
Cardiac risk factors and prevention

measurement used in analyses, or the first measure where the second was missing. A Hawksley random zero sphygmomanometer (Hawksley & Sons, Larkin, UK; a state of the art machine at the time) was used at 36 and 43 years.\(^5\)\(^6\) A validated oscillometric device (Omron HEM-705) was used in later in home visits. To enable comparison of BP measured by the different machines, the measurements from the random zero sphygmomanometer were adjusted using published conversion equations.\(^10\)

**Antihypertensive treatment and diabetes status**

Prior to clinic attendance, study members completed a postal questionnaire that included details of current medication. Antihypertensive medications for the last two rounds were classified according to International Classification of Diseases and related Health Problems classification.\(^11\) Self-reported and doctor diagnosed type 2 diabetes mellitus (T2DM) was obtained from the postal questionnaires and reports at earlier follow-ups.

**Echocardiography**

Of the 1690 participants who attended a clinic, 1653 (798 men and 855 women, mean age 63.3±1.1 years (ISD)) underwent echocardiography using GE Vivid I machines (GE, Connecticut, USA) and 1576 had at least one analyzable image (95%). Echocardiographic images were obtained from parasternal long axis and short axis, apical five-chamber, four-chamber, three-chamber, two-chamber and aortic views along with conventional and tissue Doppler in the four-chamber view. Image analysis was carried out by three experienced British Society of Echocardiography-accredited readers including the author (AKG) masked to patient identity using GE EchoPac software.

The following markers of diastolic function were measured in accordance with American Society of Echocardiography/European Association of Echocardiography recommendations—ratio of early (E) to late (A) transmitral Doppler flow (E/A), early (e') myocardial velocity at the mitral valve annulus (average of septal and lateral wall measures) e', E/e' and ratio of early and late (a') myocardial velocities at the mitral valve annulus (average of septal and lateral wall measures) e'/a'.\(^12\) E/e' was calculated as an estimate of LV filling pressure.\(^12\) Left atrial volume indexed to body surface area (LAVI) was also examined as a marker of chronically elevated LV filling pressures.\(^13\)

Quality control measures included standardised training for senior, experienced echocardiographers and readers, echocardiographer observation by trained echocardiographers, periodic reader and echocardiographer review and refresher sessions, phantom studies on ultrasound machines and continuous quality control audit throughout the period of data collection. Blind duplicate reading reproducibility studies (n=70 on two occasions) were carried out to establish inter-reader and intrareader variability. These showed excellent reproducibility (intra-class correlation coefficients were >0.90 for most measurements).

**Statistical analysis**

Statistical analysis was performed using Stata V14.1 (StataCorp LP, USA). Initially, separate regression models investigated the association between SBP at each of the 4 ages at which it was measured and measures of diastolic function at 60–64 years, with adjustment for sex, age at clinic visit and clinic attended. We examined whether associations were linear by inspection of residuals. Given evidence that cardiac function may differ by sex,\(^1\) we also investigated whether associations with SBP were subject to effect modification by sex through inclusion of a sex×SBP term in models, but this was not statistically significant in any model. Consequently, we show data from models including both sexes that were adjusted for sex. HTT at the same age as BP measurement was then added to the models. Additional models assessed whether earlier SBP remained predictive once current SBP was also included, that is, to what extent antecedent SBP was independent of current SBP. This is an important consideration given the anticipated correlations between SBP at different times within an individual (tracking). Further statistical models were constructed by including potential confounders BMI, T2DM, smoking and physical activity status at age 60–64 years. In a further model left ventricular mass indexed to body surface area (LVMI) was included with possible confounders to explore the extent to which LVMI might mediate the associations observed.

In order to maintain the sample size and minimise bias introduced by missing data in fully adjusted analyses, we employed a multiple imputation procedure to impute missing covariates. For each outcome, a total of 20 imputed datasets were obtained using chained equations implemented using imputation by chained equations in Stata. For the imputation models we included all variables in the final adjusted analytic model, each model, as well as the outcome and additional variables that helped predict the missing covariates. The regression coefficients and standard errors were calculated for each imputed dataset, and then combined using Rubin’s rule.

To investigate whether rate of change in SBP at a particular period of midlife was more strongly associated with diastolic function, we calculated the change in SBP for the periods 36–43 years, 43–53 years and 53–60/64 years conditional on earlier SBP by modelling each SBP measure (from age 43 years) on the earlier measure(s) for each sex and saving the residuals. These residuals reflect SBP velocity and can be interpreted as the change in SBP in an individual above or below that expected on average in the sample given their earlier SBP.\(^14\) The residuals were standardised (mean=0 and SD=1) to allow a comparison of the relative strength of associations between periods. We subsequently fitted regression models including all these standardised changes with each of the measures of diastolic function as the outcome. This analysis was performed only for individuals who had all variables observed (complete case analysis). Two models were constructed: model 1—adjusted for age, sex and CRF attended; model 2—model 1 +T2DM+BMI+smoking status+physical activity status+current HTT. \(p\) Values were calculated using Wald tests. Similar analyses were repeated for diastolic BP (DBP), pulse pressure (PP) and mean arterial pressure (MAP).

Sensitivity analyses were carried out to assess whether the associations with SBP remained unchanged if those who were hypertensive (SBP≥140 mm Hg or DBP≥90 mm Hg) were excluded.

**RESULTS**

Characteristics of participants with any echocardiography data at age 60–64 years are shown in table 1. Those with unanalyzable echocardiograms had higher BMIs and heart rates, but BP did not differ.\(^7\) Additional participant characteristics are presented in online supplementary table S1.

SBP from age 53 years was negatively associated with e' (table 2). This relationship weakened with progressive risk factor adjustment. HTT was negatively associated with e' in the minimally adjusted model from age 53 years.

Broadly similar findings were observed when the associations between current and antecedent SBP and E/A were examined, although relationships tended to be weaker. SBP at 53 and...
60–64 years was predictive of E/A and HTT at any age was unrelated to E/A (table 3). Data relating SBP measured at various ages to e′/a′ were consistent with observations for e′ and E/A (data not shown).

SBP from 36 years onwards was positively associated with increased e′/e′ (table 4). The relationship persisted after adjustment for age, sex, clinic attended, current HTT/DBP/BMI/T2DM/smoking/physical activity. SBP at age 53 years and HTT at age 53 years were also positively associated with LAVI (table 5). Analyses were repeated replacing SBP with DBP, PP or MAP should similar associations (data not shown).

From 43 years onwards, those on HTT had increased E/e′; this was not affected substantively by adjustment for current SBP; regression coefficients were slightly attenuated by adjustment for BMI/T2DM/smoking/physical activity although relationships remained statistically significant (table 4). We also investigated whether the effect of earlier SBP was mediated via LV hypertrophy by inclusion of LVMI into regression models. This was not the case.

We investigated whether relationships between elevated BP in earlier life and e′ and E/e′ might be driven by inclusion of people who went on to develop hypertension. However, when those who were hypertensive at 60–64 years (SBP ≥140 mm Hg or DBP ≥90 mm Hg) were excluded from the analysis, the associations remained very similar (data not shown).

We looked to see whether there was a sensitive period when rate of change in SBP had most influence on diastolic function and filling pressure. Increased rates of rise in SBP over the age periods 43–53 and 53–60/64 years were also significantly associated with worse e′ (figure 1A) and E/A (figure 1B). Increased rate of rise in SBP at all age periods (36–43 years, 43–53 years and 53–60/64 years) was associated with increased E/e′ (figure 1C), although the relationship was strongest over the period 43–53 years in the minimally adjusted model. The rate of rise in the 43–53 years period was also associated with increased LAVI (figure 1D).

DISCUSSION
BP from early midlife predicted worse diastolic function and evidence of elevated filling pressure at age 60–64 years. This effect was independent of current BP extended across the whole range of BP, and was not limited to people with hypertension or those who went on to develop hypertension at the time when diastolic function was assessed. We observed that those on HTT from early midlife had poorer diastolic function than those not on HTT even after current BP was accounted for. Further, we found that individuals showing comparatively rapid rises in SBP between 43–53 years and 53–60/64 years had worse subsequent diastolic function irrespective of their absolute level of SBP. Since the rise in BP in the UK population typically begins to accelerate around the fourth decade of life until it slows again in later life,13 we suggest that the period 40–60 years may represent a sensitive period when an accelerated rise in BP adversely influences future development of diastolic dysfunction.

There has been limited work in the past on relating antecedent BP with future diastolic function. Arnlöv et al reported that higher SBP and DBP at the age of 50 years were associated with increased e′ and E/A (table 3). Data relating SBP measured at various ages to e′/a′ were consistent with observations for e′ and E/A (data not shown).

SBP from 36 years onwards was positively associated with increased e′/e′ (table 4). The relationship persisted after adjustment for age, sex, clinic attended, current HTT/DBP/BMI/T2DM/smoking/physical activity. SBP at age 53 years and HTT at age 53 years were also positively associated with LAVI (table 5). Analyses were repeated replacing SBP with DBP, PP or MAP should similar associations (data not shown).

From 43 years onwards, those on HTT had increased E/e′; this was not affected substantively by adjustment for current SBP; regression coefficients were slightly attenuated by adjustment for BMI/T2DM/smoking/physical activity although relationships remained statistically significant (table 4). We also investigated whether the effect of earlier SBP was mediated via LV hypertrophy by inclusion of LVMI into regression models. This was not the case.

We investigated whether relationships between elevated BP in earlier life and e′ and E/e′ might be driven by inclusion of people who went on to develop hypertension. However, when those who were hypertensive at 60–64 years (SBP ≥140 mm Hg or DBP ≥90 mm Hg) were excluded from the analysis, the associations remained very similar (data not shown).

We looked to see whether there was a sensitive period when rate of change in SBP had most influence on diastolic function and filling pressure. Increased rates of rise in SBP over the age periods 43–53 and 53–60/64 years were also significantly associated with worse e′ (figure 1A) and E/A (figure 1B). Increased rate of rise in SBP at all age periods (36–43 years, 43–53 years and 53–60/64 years) was associated with increased E/e′ (figure 1C), although the relationship was strongest over the period 43–53 years in the minimally adjusted model. The rate of rise in the 43–53 years period was also associated with increased LAVI (figure 1D).
Table 2  Regression between e’ at 60–64 years and SBP and antihypertensive treatment at four time points with further adjustment for covariables

<table>
<thead>
<tr>
<th>Independent variable</th>
<th>Model 1</th>
<th>Model 2</th>
<th>Model 3</th>
<th>Model 4</th>
<th>Model 5</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β (95% CI)×10⁻³</td>
<td>p Value</td>
<td>β (95% CI)×10⁻³</td>
<td>p Value</td>
<td>β (95% CI)×10⁻³</td>
</tr>
<tr>
<td>Age 36 (n=1533)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP</td>
<td>−0.006 (−0.014 to 0.002)</td>
<td>0.125</td>
<td>−0.006 (−0.014 to 0.002)</td>
<td>0.122</td>
<td>−0.001 (−0.009 to 0.007)</td>
</tr>
<tr>
<td>Age 43 (n=1533)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP</td>
<td>−0.006 (−0.013 to 0.002)</td>
<td>0.128</td>
<td>−0.005 (−0.012 to 0.002)</td>
<td>0.171</td>
<td>0.002 (−0.067 to 0.101)</td>
</tr>
<tr>
<td>Age 53 (n=1533)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP</td>
<td>−0.011 (−0.017 to −0.006)</td>
<td>&lt;0.001</td>
<td>−0.010 (−0.016 to −0.005)</td>
<td>&lt;0.001</td>
<td>−0.005 (−0.011 to 0.001)</td>
</tr>
<tr>
<td>Age 60–64 (n=1533)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP</td>
<td>−0.017 (−0.022 to −0.012)</td>
<td>&lt;0.001</td>
<td>−0.017 (−0.022 to −0.011)</td>
<td>&lt;0.001</td>
<td>NR</td>
</tr>
<tr>
<td>Age 36</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HTT</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Age 43</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age 53</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age 60–64</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Imputed (n=1533 for all models—with valid outcome and SBP at age 60–64 years). The variable β is regression coefficient for e’ versus SBP (mm Hg) or antihypertensive treatment (HTT). Model 1: adjusted for age sex and CRF attended. Model 2: model 1 +antihypertensive treatment (HTT) at given age (for SBP) or model 1+SBP at given age (for HTT). Model 3: model 2+SBP at 60–64 years. Model 4: model 3+T2DM+BMI+smoking status—physical activity status. Model 5: model 4+left ventricular mass indexed to body surface area. Numbers of individuals receiving HTT were 51 (2%), 107 (3%), 438 (15%) and 640 (27%) at age 36, 43, 53 and 60–64 years, respectively. BMI, body mass index; CRF, clinical research facility; NR, not relevant; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus.

Table 3  Regression between E/A at 60–64 years and SBP and antihypertensive treatment at four time points with further adjustment for covariables

<table>
<thead>
<tr>
<th>Independent variable</th>
<th>Model 1</th>
<th>Model 2</th>
<th>Model 3</th>
<th>Model 4</th>
<th>Model 5</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β (95% CI)×10⁻³</td>
<td>p Value</td>
<td>β (95% CI)×10⁻³</td>
<td>p Value</td>
<td>β (95% CI)×10⁻³</td>
</tr>
<tr>
<td>Age 36 (n=1576)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP</td>
<td>0.3 (−0.8 to 1.5)</td>
<td>0.564</td>
<td>0.3 (−0.8 to 1.4)</td>
<td>0.598</td>
<td>0.9 (−0.2 to 2.1)</td>
</tr>
<tr>
<td>Age 43 (n=1576)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP</td>
<td>0.4 (−0.7 to 1.4)</td>
<td>0.481</td>
<td>0.4 (−0.6 to 1.5)</td>
<td>0.443</td>
<td>1.3 (0.2 to 2.3)</td>
</tr>
<tr>
<td>Age 53 (n=1576)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP</td>
<td>−1.4 (−2.2 to −0.7)</td>
<td>&lt;0.001</td>
<td>−1.5 (−2.3 to −0.7)</td>
<td>&lt;0.001</td>
<td>−1.0 (−1.8 to −0.1)</td>
</tr>
<tr>
<td>Age 60–64 (n=1576)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP</td>
<td>−1.8 (−2.6 to −1.1)</td>
<td>&lt;0.001</td>
<td>−1.8 (−2.6 to −1.0)</td>
<td>&lt;0.001</td>
<td>NR</td>
</tr>
<tr>
<td>Age 36</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HTT</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Age 43</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age 53</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age 60–64</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Imputed (n=1576 for all models—with valid outcome and SBP at age 60–64 years). The variable β is regression coefficient for E/A versus SBP (mm Hg) or antihypertensive treatment (HTT). Model 1: adjusted for age sex and CRF attended. Model 2: model 1+HTT at given age (for SBP) or model 1+SBP at given age (for HTT). Model 3: model 2+SBP at 60–64 years. Model 4: model 3+T2DM+BMI+smoking status—physical activity status. Model 5: model 4+left ventricular mass indexed to body surface area. Numbers of individuals receiving HTT were 51 (2%), 107 (3%), 438 (15%) and 640 (27%) at age 36, 43, 53 and 60–64 years, respectively. BMI, body mass index; CRF, clinical research facility; NR, not relevant; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus.
Table 4  Regression between E/e₀ at 60–64 years and SBP and antihypertensive treatment at four time points with further adjustment for covariables (n=1490 for all models—with valid outcome and SBP at age 60–64 years)

<table>
<thead>
<tr>
<th>Independent variable</th>
<th>Model 1</th>
<th>Model 2</th>
<th>Model 3</th>
<th>Model 4</th>
<th>Model 5</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β (95% CI)</td>
<td>p Value</td>
<td>β (95% CI)</td>
<td>p Value</td>
<td>β (95% CI)</td>
</tr>
<tr>
<td>Age 36 (n=1490) SBP</td>
<td>0.015 (0.006 to 0.024)</td>
<td>0.001</td>
<td>0.015 (0.006 to 0.024)</td>
<td>0.001</td>
<td>0.007 (−0.002 to 0.016)</td>
</tr>
<tr>
<td>Age 43 (n=1490) SBP</td>
<td>0.019 (0.011 to 0.027)</td>
<td>&lt;0.001</td>
<td>0.017 (0.009 to 0.025)</td>
<td>&lt;0.001</td>
<td>0.008 (0.000 to 0.017)</td>
</tr>
<tr>
<td>Age 53 (n=1490) SBP</td>
<td>0.022 (0.017 to 0.028)</td>
<td>&lt;0.001</td>
<td>0.020 (0.014 to 0.026)</td>
<td>&lt;0.001</td>
<td>0.013 (0.007 to 0.019)</td>
</tr>
<tr>
<td>Age 60–64 (n=1490) SBP</td>
<td>0.024 (0.019 to 0.030)</td>
<td>&lt;0.001</td>
<td>0.023 (0.018 to 0.029)</td>
<td>&lt;0.001</td>
<td>NR</td>
</tr>
<tr>
<td>Age 36 HTT NR</td>
<td>−0.06 (−1.18 to 1.06)</td>
<td>0.917</td>
<td>0.06 (−1.05 to 1.18)</td>
<td>0.909</td>
<td>0.004 (−1.08 to 1.09)</td>
</tr>
<tr>
<td>Age 43 HTT NR</td>
<td>1.38 (0.62 to 2.13)</td>
<td>&lt;0.001</td>
<td>1.34 (0.59 to 2.08)</td>
<td>&lt;0.001</td>
<td>1.13 (0.39 to 1.87)</td>
</tr>
<tr>
<td>Age 53 HTT NR</td>
<td>0.72 (0.39 to 1.05)</td>
<td>&lt;0.001</td>
<td>0.72 (0.39 to 1.04)</td>
<td>&lt;0.001</td>
<td>0.62 (0.30 to 0.95)</td>
</tr>
<tr>
<td>Age 60–64 HTT NR</td>
<td>0.69 (0.44 to 0.95)</td>
<td>&lt;0.001</td>
<td>NR</td>
<td>NR</td>
<td>0.55 (0.29 to 0.82)</td>
</tr>
</tbody>
</table>

The variable β is regression coefficient for E/e₀ versus SBP (mm Hg) or antihypertensive treatment (HTT). Model 1: adjusted for age sex and CRF attended. Model 2: model 1+HTT at given age (for SBP) or model 1+SBP at given age (for HTT). Model 3: model 2+SBP at 60–64 years. Model 4: model 3+T2DM+BMI+smoking status+physical activity status. Model 5: model 4+left ventricular mass indexed to body surface area. Numbers of individuals receiving HTT were 51 (2%), 107 (3%), 438 (15%) and 640 (27%) at age 36, 43, 53 and 60–64 years, respectively. BMI, body mass index; CRF, clinical research facility; NR, not relevant; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus.

Table 5  Regression between LAVI at 60–64 years and SBP and antihypertensive treatment at four time points with further adjustment for covariables (n=1417 for all models—with valid outcome and SBP at age 60–64 years)

<table>
<thead>
<tr>
<th>Independent variable</th>
<th>Model 1</th>
<th>Model 2</th>
<th>Model 3</th>
<th>Model 4</th>
<th>Model 5</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β (95% CI)</td>
<td>p Value</td>
<td>β (95% CI)</td>
<td>p Value</td>
<td>β (95% CI)</td>
</tr>
<tr>
<td>Age 36 (n=1417) SBP</td>
<td>0.042 (0.013 to 0.072)</td>
<td>0.005</td>
<td>0.041 (0.012 to 0.071)</td>
<td>0.006</td>
<td>0.035 (0.004 to 0.065)</td>
</tr>
<tr>
<td>Age 43 (n=1417) SBP</td>
<td>0.042 (0.013 to 0.070)</td>
<td>0.004</td>
<td>0.040 (0.011 to 0.069)</td>
<td>0.006</td>
<td>0.021 (0.001 to 0.061)</td>
</tr>
<tr>
<td>Age 53 (n=1417) SBP</td>
<td>0.056 (0.036 to 0.075)</td>
<td>&lt;0.001</td>
<td>0.047 (0.027 to 0.068)</td>
<td>&lt;0.001</td>
<td>0.043 (0.021 to 0.065)</td>
</tr>
<tr>
<td>Age 60–64 (n=1417) SBP</td>
<td>0.030 (0.009 to 0.051)</td>
<td>0.004</td>
<td>0.028 (0.008 to 0.050)</td>
<td>0.007</td>
<td>NR</td>
</tr>
<tr>
<td>Age 36 HTT NR</td>
<td>2.560 (−1.650 to 6.771)</td>
<td>0.232</td>
<td>2.769 (−1.433 to 6.971)</td>
<td>0.195</td>
<td>1.931 (−2.262 to 6.124)</td>
</tr>
<tr>
<td>Age 43 HTT NR</td>
<td>2.179 (−0.393 to 4.751)</td>
<td>0.097</td>
<td>2.205 (−0.352 to 4.762)</td>
<td>0.091</td>
<td>1.388 (−1.204 to 3.981)</td>
</tr>
<tr>
<td>Age 53 HTT NR</td>
<td>2.304 (1.139 to 3.469)</td>
<td>&lt;0.001</td>
<td>2.326 (1.161 to 3.491)</td>
<td>&lt;0.001</td>
<td>1.979 (0.799 to 3.159)</td>
</tr>
<tr>
<td>Age 60–64 HTT NR</td>
<td>1.290 (0.667 to 2.512)</td>
<td>0.001</td>
<td>−</td>
<td>NR</td>
<td>1.084 (0.134 to 2.033)</td>
</tr>
</tbody>
</table>

The variable β is regression coefficient for LAVI versus SBP (mm Hg) or antihypertensive treatment (HTT). Model 1: adjusted for age sex and CRF attended. Model 2: model 1+HTT at given age (for SBP) or model 1+SBP at given age (for HTT). Model 3: model 2+SBP at 60–64 years. Model 4: model 3+diabetes mellitus+body mass index+smoking status+physical activity status. Model 5: model 4+left ventricular mass indexed to body surface area. Numbers of individuals receiving HTT were 51 (2%), 107 (3%), 438 (15%) and 640 (27%) at age 36, 43, 53 and 60–64 years, respectively. CRF, clinical research facility; LAVI, left atrial volume indexed to body surface area; NR, not relevant; SBP, systolic blood pressure.
with decreased E/A measured 20 years later in the Swedish Uppsala cohort. Hypertension is thought to cause diastolic dysfunction via impaired LV relaxation and reduced LV compliance. Ultimately, the elevated filling pressures associated with severe diastolic dysfunction can lead to HFPEF or pulmonary oedema. Interestingly, Lee et al reported that higher BP and BMI in midlife were predictive of incident heart failure in later life in the Framingham study. Our data suggest that this relationship may be mediated at least in part via diastolic dysfunction.

Randomised clinical trials such as Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) and HYpertension in the Very Elderly Trial (HYVET) have demonstrated the benefits of treating hypertension in terms of decreased incidence of new heart failure and heart failure admissions. However, optimal management of diastolic dysfunction remains unclear: trials in HFPEF have demonstrated little or no benefit with conventional heart failure medication. There is evidence for improvement in diastolic function with short-term HTT, but longer-term HTT was not associated with improvement of diastolic function despite regression of LV mass in a substudy of the Anglo Scandinavian Cardiac Outcomes trial. Nevertheless, BP control is considered a cornerstone of management of these patients. In our cohort we found that from 43 years onwards, for any given level of BP (including for BP in the normal range, those on HTT had worse diastolic function at 60–64 years than those not on HTT). These data should not be interpreted as indicating that antihypertensive therapy has a negative effect on diastolic function, the observational design of the study precludes any such interpretation. Possible explanations of this finding include: inadequate long-term control of BP despite treatment—it should be noted that only approximately half of hypertensive participants were controlled to <140/90 mm Hg at age 60–64 years; or the accrual of some BP–related damage prior to initiation of treatment. If the latter were true, individuals at risk may need to be treated at an earlier age and/or to lower target BP.

Elevated antecedent BP is associated with LV hypertrophy, and this could contribute to impaired diastolic function; however, adjustment for LVMI only moderately attenuated associations between antecedent BP and diastolic function and it seems that associations, particularly for E/e' and LAVI, are independent of increased LVMI. Some cross-sectional studies have found PP to be the best predictor of diastolic function, but we found relatively similar associations between antecedent SBP, PP and MAP and diastolic function.

Figure 1 Association between standardised residuals of change in systolic blood pressure (SBP) over three time periods (36–43 years), (43–53 years) and (53–60 to 64 years) conditional on the earlier measure(s) and markers of diastolic function at age 60–64 years. The residuals can be interpreted as the standardised rate of change in SBP in an individual above or below that expected on average in the sample given their earlier SBP. (A) e' at age 60–64 years (n=1172). (B) E/A at age 60–64 years (n=1190). (C) E/e' at age 60–64 years (n=1120). (D) Left atrial volume indexed to body surface area at age 60–64 years (n=1054). Data points are β coefficients and the bars represent 95% CIs. Model 1 (♣): model 1+diabetes mellitus+body mass index+smoking status+physical activity status+current antihypertensive treatment. p Values were calculated using Wald tests and p<0.05 indicates a significant association between the rate of change in SBP in the specified period and the measure of diastolic function.

Cardiac risk factors and prevention

Strengths and limitations

Our findings are derived from a nationally representative sample of native-born British people born in 1946. Using the life course approach in relating BP at different ages and change in BP over time to future diastolic function is unique and is a major strength of our study. This was only possible due to detailed repeated measurements of risk factors and recording of HTT in our study, which is the longest running birth cohort in the UK. Studies of birth cohorts have a number of advantages, notably that accounting for the effect of age is much less problematic. We used tissue Doppler as our primary measure of diastolic function, this has the advantage that it can distinguish normal diastolic function from pseudonormalisation. Pseudonormalisation will tend to attenuate relationships between antecedent BP and diastolic function assessed by E/A, and probably accounts for the generally weaker relationships seen using this measure of diastolic function. Missing data are inevitable in studies as long-running as the MRC NSHD (≥60 years), although participant retention was good in comparison with other cohorts. Compared with those study members who attended clinic for clinical examination and echocardiography, those who only had clinical examinations at home visits had higher BMI and heart rates. However, participation of relatively more healthy individuals in the echocardiography study is, if anything, likely to have weakened relationships between BP and diastolic function. There were no measurements of BP prior to 36 years, and hence we cannot comment on the importance of BP in earlier life periods. We are limited to identifying a sensitive period from three intervals as the study has only four measures of BP. This lack of BP measurements in limits our ability to determine whether BP control was optimal between measurements. Echocardiography was only carried out in the last round of data collection; hence the possibility of diastolic dysfunction preceding the rise in BP cannot be excluded, although such a relationship seems unlikely.

CONCLUSIONS

BP from the age of 36 years predicts diastolic function in people aged 60–64 years independently of current BP (for E/A and LAVI); faster increases in BP in midlife are particularly detrimental. People on HTT have more adverse diastolic function even when current BP is taken into account suggesting that early risk factor modification may be important to prevent the adverse effects of BP on diastolic function.

Acknowledgements

We thank the NSHD study members who took part in the clinic data collection for their continuing support. We thank members of the NSHD scientific and data collection teams at the MRC Unit for Lifelong Health and Ageing at UCL and the six Clinical Research Facilities.

Contributors

AKG, RH and ADH conceived and designed the research and carried out the statistical analyses. DK secured funding for the study. All authors critically reviewed the manuscript. A KG, ADH and RH are responsible as guarantors for the overall content.

Funding

The authors are/were employees of one of the following organisations: Barts Health NHS Trust, University College London or Imperial College. DP, ADH and JM received support from the Imperial College Academic Health Sciences Biomedical Research Centre. NC, JD and ADH received support from the University College Academic Health Sciences Biomedical Research Centre. NSHD, AKG, RH and DK were supported by the UK Medical Research Council (MC_UU_12018/1 and MC_UU_12019/2).

Competing interests

None declared.

Ethics approval

The Central Manchester Local Research Ethics Committee—(07/H1008/168) and the Scotland A Research Ethics Committee.

Provenance and peer review

Not commissioned; externally peer reviewed.

Open Access

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

REFERENCES


Key messages

What is already known on this subject?

► High blood pressure (BP) is associated with diastolic dysfunction in cross-sectional studies.
► Very little is known about the longitudinal effects of high BP and changes in BP over adult life on future diastolic function.

What might this study add?

► High blood pressure (BP) levels, and rises in BP in midadult life adversely affect diastolic function up to 28 years later.
► Hypertensive individuals have worse diastolic function even when their current BP was taken into account.

How might this impact on clinical practice?

► Early identification of those with fast rising blood pressure (BP) (even in the ‘normal’ BP range) may be important to prevent diastolic dysfunction in later life.
Midlife blood pressure predicts future diastolic dysfunction independently of blood pressure

Arjun Kumar Ghosh, Alun David Hughes, Darrel Francis, Nishi Chaturvedi, Denis Pellerin, John Deanfield, Diana Kuh, Jamil Mayet and Rebecca Hardy

Heart published online April 7, 2016

Updated information and services can be found at:
http://heart.bmj.com/content/early/2016/04/07/heartjnl-2015-308836

These include:

References
This article cites 30 articles, 6 of which you can access for free at:
http://heart.bmj.com/content/early/2016/04/07/heartjnl-2015-308836
#BIBL

Open Access
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See:
http://creativecommons.org/licenses/by/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Open access (175)
Hypertension (2949)
Clinical diagnostic tests (4723)
Echocardiography (2089)
Drugs: cardiovascular system (8702)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/